New Triple-Threat attack on spreading prostate cancer
NCT ID NCT04126070
Summary
This study is testing whether adding an immunotherapy drug (nivolumab) to standard hormone therapy and chemotherapy can better control prostate cancer that has already spread. It is for men newly diagnosed with a high amount of spreading cancer. The goal is to see if this three-drug combination is safe and more effective at lowering PSA levels and controlling the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
H. Lee Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
The Johns Hopkins University School of Medicine
Baltimore, Maryland, 21218, United States
-
University of California, San Diego
La Jolla, California, 92093, United States
-
University of Wisconsin
Madison, Wisconsin, 53706, United States
Conditions
Explore the condition pages connected to this study.